



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

尼拉帕尼甲苯磺酸盐

货号: T92613

规格: 1ml

保存温度: -80℃ 保存。

溶解性数据:

体外实验:

DMSO : 100 mg/mL (203.01 mM; ultrasonic and warming and heat to 60℃)

H₂O : 1 mg/mL (2.03 mM; heat to 50℃)

	Concentration	1 mg	5 mg	10 mg
制备储备液	1 mM	2.0301 mL	10.1504 mL	20.3009 mL
	5 mM	0.4060 mL	2.0301 mL	4.0602 mL
	10 mM	0.2030 mL	1.0150 mL	2.0301 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80℃，1 year；-20℃，6 months (sealed storage, away from moisture)。-80℃ 储存时，请在 1 年内使用，-20℃ 储存时，请在 6 个月内使用。

体内实验:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

2. 请依序添加每种溶剂: 5% DMSO 95% (20% SBE- β -CD in saline) Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution

3. 请依序添加每种溶剂: 1% DMSO 99% saline Solubility: ≥ 0.5 mg/mL (1.02 mM); Clear solution

BIOLOGICAL ACTIVITY:

生物活性:

Niraparib tosylate (MK-4827 tosylate) 是一种高效的, 具有生物口服利用度的 PARP1 和 PARP2 抑制剂, IC₅₀ 分别为 3.8 和 2.1 nM。Niraparib tosylate 抑制 DNA 损伤修复, 诱导凋亡 (apoptosis) 并具有抗肿瘤活性。

IC₅₀ & Target:

PARP-2: 2.1 nM (IC₅₀)

PARP-1: 3.8 nM (IC₅₀)

V-PARP: 330 nM (IC₅₀)

TANK-1: 570 nM (IC₅₀)

PARP-3: 1300 nM (IC₅₀)

体外研究:

Niraparib (MK-4827) inhibits PARP activity with EC₅₀=4 nM and EC₉₀=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC₅₀ in the 10-100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC₅₀=3.8 and 2.1 nM, respectively, and in a whole cell assay.

To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μ M Niraparib (MK-4827) for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.

体内研究:



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution ($V_{dss}=6.9$ L/kg), long terminal half-life ($t_{1/2}=3.4$ h), and excellent bioavailability, $F=65\%$.

Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily.

PROTOCOL:

Cell Assay:

The inhibition of PARP is analyzed in A549 and H1299 cells using the HT Universal Chemiluminescent PARP Assay Kit. Briefly, cells are treated with DMSO or 1 μ M Niraparib (MK-4827) for 15, 30, 60, or 120 minutes, trypsinized, and transferred to a pre-chilled tube. The cells are washed twice with ice cold PBS and resuspended in cold PARP extraction buffer. The cell suspensions are incubated on ice for 30 minutes with periodic vortexing to disrupt the cell membrane. The suspensions are centrifuged and the supernatant transferred to a pre-chilled tube on ice. The histone coated wells of the 96-well plate are rehydrated with 1X PARP buffer and incubated at room temperature for 30 minutes. The PARP buffer is removed and 20 μ g of protein as determined by the Bio-Rad Protein Assay is added to each well followed by diluted PARP-HSA enzyme and 1X PARP buffer. The strip wells are then incubated at room temperature for 60 minutes, washed twice with PBS containing 0.1% Triton X-100, and then washed with PBS. Diluted Strep-HRP is added to the strip wells and incubated for 60 minutes at room temperature. The wells are washed again as before. Equal volumes of PeroxyGlow A and B are combined and



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

added to the wells and chemiluminescent readings are obtained immediately using a plate-reader.

Animal:

Mice

Administration:

Female nude mice (Ncr Nu/Nu) are randomly assigned to treatment groups consisting of 5 to 8 mice each when tumors grew to 6.0 mm in diameter at which time treatment with MK-4827 is initiated. MK-4827 is given at a dose of 25 mg/kg twice daily or 50 mg/kg once daily for either 21 days or is discontinued at 9 days from the time tumors reached 8 mm in diameter. Fractionated local tumor irradiation (XRT) is given when tumors reach 8.0 mm in diameter (7.7-8.2 mm). Radiation (2 Gy per fraction) is delivered to the tumor-bearing leg of mice once daily for 14 consecutive days or twice daily for 7 consecutive days using a small-animal irradiator consisting of two parallel-opposed ¹³⁷Cs sources, at a dose rate of 5 Gy/min. During irradiation un-anesthetized mice are mechanically immobilized in a jig so that the tumor is centered within a 3.0 cm diameter radiation field and the animal's body shielded from radiation exposure. On the day when both MK-4827 and radiation are given, drug is administered 1 h before the first radiation dose of the day.